Patrick van Berkel

Dr. van Berkel has more than 20 years of experience in the biotech industry, specializing in the development of antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. van Berkel spent more than 9 years with Genmab in various roles, including Vice President of Antibody Technology and Vice President of CMC R&D.

Dr. van Berkel has a chemistry degree from the University of Nijmegen, The Netherlands (1991), and did his thesis at the University of Leiden, The Netherlands (1998).